表紙
市場調査レポート

感染性下痢症:パイプライン製品の分析

Infectitious Diarrhea - Pipeline Review, H2 2014

発行 Global Markets Direct 商品コード 271847
出版日 ページ情報 英文 82 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
感染性下痢症:パイプライン製品の分析 Infectitious Diarrhea - Pipeline Review, H2 2014
出版日: 2014年11月18日 ページ情報: 英文 82 Pages
概要

感染性下痢症は、細菌、ウイルス、寄生虫による消化器系の感染症です。頻繁な排便、水様便、発熱、悪寒、食欲不振、嘔吐、倦怠感、頭痛、筋肉痛、腹痛などの兆候や症状があります。

当レポートでは、感染性下痢症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

感染性下痢症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Actelion Ltd
  • Cubist Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Paratek Pharmaceuticals, Inc.
  • Napo Pharmaceuticals, Inc.
  • MGB Biopharma Limited

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • surotomycin
  • crofelemer DR
  • fidaxomicin
  • cadazolid
  • fidaxomicin
  • AKT-10081
  • MGB-BP-3
  • PF-06425090
  • Capsule Conjugate Vaccine for Campylobacter Caused Diarrhea
  • Tetracycline Derivatives For CDAD
  • PZ-7475
  • Clostridium difficile Vaccine
  • Enterotoxigenic Escherichia coli Vaccine
  • Peptide for Enterocolitis and Infectious Diarrhea
  • Fucosylated Glycoproteins

パイプライン製品の最新動向

休止状態のプロジェクト

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC5713IDB

Summary

Global Markets Direct's, 'Infectitious Diarrhea - Pipeline Review, H2 2014', provides an overview of the Infectitious Diarrhea's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Infectitious Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Infectitious Diarrhea and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Infectitious Diarrhea
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Infectitious Diarrhea and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Infectitious Diarrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Infectitious Diarrhea pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Infectitious Diarrhea
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Infectitious Diarrhea pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Infectitious Diarrhea Overview
  • Therapeutics Development
    • Pipeline Products for Infectitious Diarrhea - Overview
    • Pipeline Products for Infectitious Diarrhea - Comparative Analysis
  • Infectitious Diarrhea - Therapeutics under Development by Companies
  • Infectitious Diarrhea - Therapeutics under Investigation by Universities/Institutes
  • Infectitious Diarrhea - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Infectitious Diarrhea - Products under Development by Companies
  • Infectitious Diarrhea - Products under Investigation by Universities/Institutes
  • Infectitious Diarrhea - Companies Involved in Therapeutics Development
    • Actelion Ltd
    • Assembly Biosciences, Inc.
    • Cubist Pharmaceuticals, Inc.
    • Napo Pharmaceuticals, Inc.
    • Paratek Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Prokarium Ltd.
    • Shire Plc
    • Summit Corporation plc
  • Infectitious Diarrhea - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AKT-10081 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cadazolid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • clostridium difficile vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • crofelemer DR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for CDAD - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fidaxomicin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • infectious diarrhea vaccine [serotype H11] (H10407 and E24377A) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptide for Enterocolitis and Infectious Diarrhea - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PF-06425090 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PZ-7475 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RBX-2660 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Diarrhea - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Infectious Diarrhea - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SMT-19969 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • surotomycin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Tetracycline Derivatives for CDAD - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Campylobacter Caused Diarrhea - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VP-20621 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Infectitious Diarrhea - Recent Pipeline Updates
  • Infectitious Diarrhea - Dormant Projects
  • Infectitious Diarrhea - Product Development Milestones
    • Featured News & Press Releases
      • Feb 25, 2014: Salix Wins Napo Pharmaceuticals Litigation
      • Jan 14, 2014: Fulyzaq 125 mg Delayed-Release Tablets Significantly Improves Noninfectious Diarrhea in Adult Patients Living with HIV on ART Therapy
      • Dec 21, 2012: Actelion's Cadazolid To Move Into Phase III Clinical Development In Patients With Clostridium Difficile Associated Diarrhea
      • Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate CB-315 At ICAAC 2012
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Infectitious Diarrhea, H2 2014
  • Number of Products under Development for Infectitious Diarrhea - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Infectitious Diarrhea - Pipeline by Actelion Ltd, H2 2014
  • Infectitious Diarrhea - Pipeline by Assembly Biosciences, Inc., H2 2014
  • Infectitious Diarrhea - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014
  • Infectitious Diarrhea - Pipeline by Napo Pharmaceuticals, Inc., H2 2014
  • Infectitious Diarrhea - Pipeline by Paratek Pharmaceuticals, Inc., H2 2014
  • Infectitious Diarrhea - Pipeline by Pfizer Inc., H2 2014
  • Infectitious Diarrhea - Pipeline by Prokarium Ltd., H2 2014
  • Infectitious Diarrhea - Pipeline by Shire Plc, H2 2014
  • Infectitious Diarrhea - Pipeline by Summit Corporation plc, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Infectitious Diarrhea Therapeutics - Recent Pipeline Updates, H2 2014
  • Infectitious Diarrhea - Dormant Projects, H2 2014

List of Figures

  • Number of Products under Development for Infectitious Diarrhea, H2 2014
  • Number of Products under Development for Infectitious Diarrhea - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Targets, H2 2014
  • Number of Products by Stage and Top 10 Targets, H2 2014
  • Number of Products by Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Top 10 Routes of Administration, H2 2014
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2014
  • Number of Products by Top 10 Molecule Types, H2 2014
  • Number of Products by Stage and Top 10 Molecule Types, H2 2014
Back to Top